We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Acarbose (Precose, Glucobay)
An oral diabetes drug (alpha-glucosidase inhibitor) that blunts post-meal glucose spikes. It robustly extended lifespan in male mice in the NIA aging program and reduced cardiovascular events in human prevention trials. Human longevity benefit is unproven; the main downside is gas/GI side effects. A prescription drug taken off-label, not a supplement.
Prescription medication — not a dietary supplement
Acarbose is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Acarbose doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1999–2026.
Based on 198 studies · 11 meta-analyses · 166 RCTs
Confidence
High confidenceBy outcome
Acarbose robustly extended lifespan in male mice (NIA ITP) and reduced cardiovascular events and diabetes progression in human prevention trials, but no human study shows it extends lifespan, and GI side effects limit tolerability — so the longevity use is promising but unproven and off-label.
161 randomised trials
86% were about Acarbose in an audit of 50 of them
Every randomised or controlled trial of Acarbose indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
5 trials ongoing or recruiting · 76 completed on ClinicalTrials.gov
13 of the completed trials have posted results
Registered trials show research momentum for Acarbose, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Acarbose is an alpha-glucosidase inhibitor that slows the breakdown of complex carbohydrates in the gut, blunting post-meal (postprandial) glucose and insulin spikes — in effect a partial 'carbohydrate blocker.' It is FDA-approved for type-2 diabetes.
Its geroscience credentials are strong for an oral drug: in the NIA Interventions Testing Program, acarbose robustly extended lifespan in genetically heterogeneous mice (most strikingly in males), one of the more reproducible pharmacological longevity results.
In humans, the STOP-NIDDM trial showed acarbose reduced progression to diabetes and lowered cardiovascular events and new hypertension in people with impaired glucose tolerance, and other trials/meta-analyses support a cardiovascular signal tied to flattening postprandial glucose.
The honest gap, as with the other geroprotectors, is that no human trial shows acarbose extends lifespan or healthspan. Its tolerability ceiling is gastrointestinal: undigested carbohydrate reaching the colon causes flatulence, bloating, and diarrhea, which is dose-limiting for many.
It is generally safe (it is not systemically absorbed much), inexpensive, and does not cause hypoglycemia on its own. Acarbose is a prescription drug used off-label for longevity/glucose-smoothing; it is not a dietary supplement.
The score reflects robust animal lifespan data and real human cardiovascular/glycemic benefit against unproven human longevity and GI tolerability limits.
Acarbose inhibits intestinal alpha-glucosidase enzymes, slowing complex-carbohydrate digestion and blunting the post-meal glucose and insulin surge.
Lower glucose/insulin excursions reduce glycemic variability — the proposed basis of both its cardiovascular and longevity effects.
Carbohydrate reaching the colon feeds fermentation, raising short-chain fatty acids — a proposed contributor to the lifespan effect (and the GI side effects).
How Acarbose works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid — increased colonic gas and osmotic load worsen symptoms.
Watch for hypoglycemia; treat with glucose, not table sugar.
Limited benefit — acarbose only acts on dietary carbohydrate.
Combination can cause hypoglycemia — treat with glucose (not sucrose), since acarbose blocks sucrose digestion.
May reduce acarbose's effect.
Tip: Start low and titrate; improves over weeks as the gut adapts.
Tip: Dose-related; reduce dose if troublesome.
Tip: Reversible; more likely at high doses — monitor on long-term high-dose use.
Acarbose has an evidence score of 4/10 — emerging evidence based on 198 indexed studies. An oral diabetes drug (alpha-glucosidase inhibitor) that blunts post-meal glucose spikes. It robustly extended lifespan in male mice in the NIA aging program and reduced cardiovascular events in human prevention trials. Human longevity benefit is unproven; the main downside is gas/GI side effects. A prescription drug taken off-label, not a supplement. Representative study: PMID 12876091.
Dosing for Acarbose: Off-label use mirrors diabetes dosing: taken with the first bite of carbohydrate-containing meals, titrated from a low dose (e.g. 25 mg) up to 50–100 mg per meal as GI tolerance allows. A prescription drug, not an approved longevity regimen. Individual needs vary, so check the right dose for you with a healthcare provider.
The best time to take Acarbose is with meals. Take it with food. Must be taken with the first bite of a carbohydrate-containing meal to inhibit carb digestion; ineffective without dietary carbohydrate.
Acarbose has a safety rating of "moderate". That is a category, not a measure of individual risk, and there are precautions worth knowing. Reported side effects include elevated liver enzymes, flatulence / bloating, diarrhea / abdominal discomfort. How often they occur is not established for all of them. Use caution if any of these apply to you: Inflammatory bowel disease / intestinal obstruction; Cirrhosis; Diabetic ketoacidosis.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism. Its only head-to-head trial with metformin cited here was a 36-person pilot, which does not show it can replace metformin.
Canagliflozin
Too few graded studiesAn SGLT2-inhibitor diabetes drug (Invokana) that lowers glucose by excreting it in urine. It extended lifespan in male mice in the NIA aging program, and the SGLT2 class has strong proven cardiovascular, kidney, and heart-failure benefits in humans. Longevity benefit itself is unproven; carries genital-infection and (rarely) ketoacidosis risks. Prescription drug, not a supplement.
Empagliflozin
Too few graded studiesAn SGLT2-inhibitor diabetes drug (Jardiance) with the strongest human outcome evidence of its class — it cuts cardiovascular death, heart-failure hospitalization, and kidney-disease progression even in non-diabetics. The most widely used SGLT2 for off-label 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement.
Dapagliflozin
Too few graded studiesAn SGLT2-inhibitor diabetes drug (Farxiga/Forxiga) with broad, robust human outcome evidence — it cuts heart-failure hospitalization and cardiovascular death across the ejection-fraction spectrum and slows kidney-disease progression, including in non-diabetics. The sibling of empagliflozin, used off-label for 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 199 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research